Xenon Pharmaceuticals (NASDAQ:XENE) has seen its price target elevated from $48.00 to $49.00 by Wells Fargo & Company, according to a research report released on February 23, 2024. This adjustment reflects the firm’s continued confidence in the biopharmaceutical company, which is currently rated as “overweight” by the investment bank.
Several other analysts have also recently weighed in on Xenon’s stock. The Royal Bank of Canada raised its price objective for Xenon shares from $55.00 to $58.00, maintaining an “outperform” rating. This announcement was made in a note on November 4, 2024. In addition, Chardan Capital upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a report issued on November 19, 2024. Conversely, Weiss Ratings reaffirmed a “sell (d-)” rating on the stock earlier this month.
Analysts have generally expressed a positive outlook on Xenon, with two rating the stock as a strong buy, eleven as a buy, and one as a sell. According to data from MarketBeat, the consensus rating for the company stands at “buy,” with an average target price of $55.50.
Financial Performance and Market Activity
Xenon Pharmaceuticals recently reported its earnings results for the fourth quarter of the fiscal year. On February 26, 2024, the company announced an earnings per share (EPS) of ($1.31), which fell short of analysts’ expectations of ($1.20). In the same quarter the previous year, the EPS was reported at ($0.84). Analysts predict that Xenon Pharmaceuticals will post an average EPS of ($3.10) for the current fiscal year.
In related news, Ian Mortimer, the company’s CEO, sold 40,000 shares of the firm’s stock on January 2, 2024, at an average price of $44.43, totaling approximately $1.78 million. Following this transaction, Mortimer retains 6,000 shares valued at about $266,580, which represents an 86.96% decrease in his holdings. The transaction details were disclosed in a filing with the Securities & Exchange Commission.
Institutional Investment Trends
Recent changes in institutional ownership reflect growing interest in Xenon Pharmaceuticals. In the second quarter, Elevation Point Wealth Partners LLC acquired a new position in the company, investing approximately $32,000. Similarly, Danske Bank A S made a new stake purchase in the third quarter, valued at around $32,000.
In a notable move, Blue Trust Inc. increased its position by a staggering 2,560.7% in the fourth quarter, now owning 745 shares, valued at $33,000. Other institutional investors, including Kestra Advisory Services LLC and Aster Capital Management DIFC Ltd, have also established new positions, contributing to a substantial institutional ownership level of 95.45% of the company’s stock.
Overall, the activity surrounding Xenon Pharmaceuticals illustrates a dynamic investment landscape, with ongoing interest from both analysts and institutional investors. As the company continues to develop its pipeline of innovative therapies targeting neurological and pain disorders, market attention remains focused on its performance and future potential.
